Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Mar 6;82(7):1348–1352. doi: 10.1054/bjoc.1999.1103

Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women

J Cuzick 1, G Terry 1,2, L Ho 1,2, J Monaghan 3, A Lopes 3, P Clarkson 4, I Duncan 5
PMCID: PMC2374489  PMID: 10755413

Abstract

Cervical scrapes from 116 British women referred with cervical cancer were tested for the presence of high oncogenic risk human papillomavirus (HPV) genotypes (HPVhr). Ninety-four per cent of the scrapes had one or more of these virus types and 66% were HPV16-positive. HPV18 was more frequent in adenocarcinoma. No evidence was found for an increased cancer risk associated with the HPV16 E6 350G variant. The HLA DRB1* and DQB1* alleles in these women and in 155 women with normal cytology and negative for HPVhrDNA were compared. DQB1*0301 alone (2P = 0.02) and in combination with DRB1*0401 (2P = 0.02) was found to be associated with cervical cancer. This was more marked in cancers positive for HPV types other than HPV16. In contrast, DRB1*1501 alone and in combination with DQB1*0602 was not significantly elevated in cancers overall, but did show some excess in HPV16-positive cancers (2P = 0.05), associated with HPV16-positive cervical cancers. Taking all cancers together, a marginally significant protective effect was found for DQB1*0501 (2P = 0.03) but no protective effect could be seen for DRB1*1301. © 2000 Cancer Research Campaign

Keywords: HPV, HLA, cervical cancer

Full Text

The Full Text of this article is available as a PDF (63.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apple R. J., Erlich H. A., Klitz W., Manos M. M., Becker T. M., Wheeler C. M. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat Genet. 1994 Feb;6(2):157–162. doi: 10.1038/ng0294-157. [DOI] [PubMed] [Google Scholar]
  2. Bontkes H. J., van Duin M., de Gruijl T. D., Duggan-Keen M. F., Walboomers J. M., Stukart M. J., Verheijen R. H., Helmerhorst T. J., Meijer C. J., Scheper R. J. HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer. 1998 Oct 5;78(2):166–171. doi: 10.1002/(sici)1097-0215(19981005)78:2<166::aid-ijc8>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  3. Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I., Lorincz A., Chan W. K., Krausz T., Soutter P. HPV testing in primary screening of older women. Br J Cancer. 1999 Oct;81(3):554–558. doi: 10.1038/sj.bjc.6690730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Duggan-Keen M. F., Keating P. J., Stevens F. R., Sinnott P., Snijders P. J., Walboomers J. M., Davidson S., Hunter R. D., Dyer P. A., Stern P. L. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur J Immunogenet. 1996 Aug;23(4):275–284. doi: 10.1111/j.1744-313x.1996.tb00123.x. [DOI] [PubMed] [Google Scholar]
  5. Hildesheim A., Schiffman M. H., Gravitt P. E., Glass A. G., Greer C. E., Zhang T., Scott D. R., Rush B. B., Lawler P., Sherman M. E. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994 Feb;169(2):235–240. doi: 10.1093/infdis/169.2.235. [DOI] [PubMed] [Google Scholar]
  6. Hildesheim A., Schiffman M., Scott D. R., Marti D., Kissner T., Sherman M. E., Glass A. G., Manos M. M., Lorincz A. T., Kurman R. J. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1035–1041. [PubMed] [Google Scholar]
  7. Londesborough P., Ho L., Terry G., Cuzick J., Wheeler C., Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer. 1996 Oct 21;69(5):364–368. doi: 10.1002/(SICI)1097-0215(19961021)69:5<364::AID-IJC2>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  8. Lorincz A. T., Reid R., Jenson A. B., Greenberg M. D., Lancaster W., Kurman R. J. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992 Mar;79(3):328–337. doi: 10.1097/00006250-199203000-00002. [DOI] [PubMed] [Google Scholar]
  9. Nindl I., Rindfleisch K., Lotz B., Schneider A., Dürst M. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer. 1999 Jul 19;82(2):203–207. doi: 10.1002/(sici)1097-0215(19990719)82:2<203::aid-ijc9>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  10. Odunsi K., Terry G., Ho L., Bell J., Cuzick J., Ganesan T. S. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer. 1996 Sep 4;67(5):595–602. doi: 10.1002/(SICI)1097-0215(19960904)67:5<595::AID-IJC1>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  11. Randal J. A call to redefine where cancer begins. J Natl Cancer Inst. 1995 Jan 18;87(2):78–80. doi: 10.1093/jnci/87.2.78. [DOI] [PubMed] [Google Scholar]
  12. Sanjeevi C. B., Hjelmström P., Hallmans G., Wiklund F., Lenner P., Angström T., Dillner J., Lernmark A. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer. 1996 Nov 15;68(4):409–414. doi: 10.1002/(SICI)1097-0215(19961115)68:4<409::AID-IJC1>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  13. Terry G., Ho L., Cuzick J. Analysis of E2 amino acid variants of human papillomavirus types 16 and 18 and their associations with lesion grade and HLA DR/DQ type. Int J Cancer. 1997 Nov 27;73(5):651–655. doi: 10.1002/(sici)1097-0215(19971127)73:5<651::aid-ijc7>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  14. Wank R., Schendel D. J., Thomssen C. HLA antigens and cervical carcinoma. Nature. 1992 Mar 5;356(6364):22–23. doi: 10.1038/356022b0. [DOI] [PubMed] [Google Scholar]
  15. Wheeler C. M., Yamada T., Hildesheim A., Jenison S. A. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J Clin Microbiol. 1997 Jan;35(1):11–19. doi: 10.1128/jcm.35.1.11-19.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Xi L. F., Koutsky L. A., Galloway D. A., Kuypers J., Hughes J. P., Wheeler C. M., Holmes K. K., Kiviat N. B. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997 Jun 4;89(11):796–802. doi: 10.1093/jnci/89.11.796. [DOI] [PubMed] [Google Scholar]
  17. Yamada T., Wheeler C. M., Halpern A. L., Stewart A. C., Hildesheim A., Jenison S. A. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995 Dec;69(12):7743–7753. doi: 10.1128/jvi.69.12.7743-7753.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zehbe I., Voglino G., Delius H., Wilander E., Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet. 1998 Oct 31;352(9138):1441–1442. doi: 10.1016/S0140-6736(05)61263-9. [DOI] [PubMed] [Google Scholar]
  19. Zehbe I., Wilander E., Delius H., Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 1998 Feb 15;58(4):829–833. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES